Related Experiment Video
Updated: Jul 17, 2026
09:51
Human Liver Spheroids from Peripheral Blood for Liver Disease Studies
Published on: January 27, 2023
Cytochrome P450 enzyme isoforms and their therapeutic implications: an update
1Department of Pharmacology, Maulana Azad Medical College, Bahadur Shah Zafar Marg, New Delhi - 110 002, India. drbskalra@gmail.com
Indian Journal of Medical Sciences
|January 30, 2007
Summary
Understanding drug metabolism enzymes, like cytochrome P450 (CYP-450), is crucial for clinicians to predict and manage potential drug-drug interactions effectively. Familiarity with substrates, inhibitors, and inducers improves patient safety.
Area of Science:
- Pharmacology
- Drug Metabolism
- Clinical Pharmacy
Background:
- Drug-drug interactions (DDIs) pose a significant clinical challenge.
- Cytochrome P450 (CYP-450) isoenzymes are central to drug metabolism.
- Predicting DDIs is essential for safe and effective pharmacotherapy.
Purpose of the Study:
- To highlight the importance of understanding CYP-450 enzyme characteristics.
- To emphasize the role of substrates, inhibitors, and inducers in DDIs.
- To guide clinicians in managing potential drug interactions.
Main Methods:
- Review of literature on CYP-450 enzyme pathways.
- Analysis of factors influencing drug metabolism.
- Synthesis of knowledge regarding substrates, inhibitors, and inducers.
Main Results:
- CYP-450 isoenzymes significantly influence drug pharmacokinetics.
- Knowledge of enzyme substrates, inhibitors, and inducers aids in predicting DDIs.
- Factors like genetics, age, and disease also impact drug metabolism.
Conclusions:
- Clinicians must be aware of CYP-450 substrates, inhibitors, and inducers.
- Understanding these factors improves the anticipation and management of DDIs.
- Enhanced knowledge of drug metabolism pathways leads to better clinical decision-making.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...